A recent systematic review and meta-analysis found that palliative care was not associated with improvement in quality of life (QOL) in terminal noncancer illness. Among potential reasons for a null effect, it is unclear if patient-reported outcome measures (PROMs) measuring QOL were derived or validated among populations with advanced life-limiting illness (ALLI).
Objective:
To systematically review the derivation and validation of QOL PROMs from a recent meta-analysis of randomized controlled trials (RCT) of palliative care interventions in people with terminal noncancer illness.
Evidence Review:
EMBASE, MEDLINE, and PsycINFO were searched from inception to January 8, 2023 for primary validation studies of QOL PROMs in populations with ALLI, defined as adults with a progressive terminal condition and an estimated median survival of less than or equal to one year. The primary outcome was the proportion of PROMs that were derived or validated in ≥1 ALLI population.
Findings:
Twenty-one unique studies of derivation (n = 13) and validation (n = 11, 3 studies evaluated both) provided data on 9657 participants (mean age 63 years, 50% female) across 15 unique QOL PROMs and subscales. Among studies of validation, 9 were in people with cancer (n = 2289, n = 5 PROMs), 1 in neurodegenerative disease (n = 23, n = 1 PROM), and 1 with mixed diseases (n = 248, n = 1 PROM). Across 15 QOL PROMs and subscales, 47% (n = 7) were derived or validated in an ALLI population. The majority of these seven PROMs were exclusively derived or validated among people with cancer (57%, n = 4). QOL PROMs such as Quality of Life at End of Life, EuroQoL-5 Dimension 5-level, and 36-item Short Form Survey demonstrated validity in more than one terminal noncancer illness.
Conclusions:
Most QOL PROMs that measured the effect of palliative care on QOL in RCTs were neither derived nor validated in an ALLI population. These findings raise questions about the inferences that palliative care does not improve QOL among people with terminal noncancer illness.
Get full access to this article
View all access options for this article.
References
1.
KavalieratosD, CorbelliJ, ZhangD, et al.Association between palliative care and patient and caregiver outcomes. JAMA, 2016; 316(20):2104; doi: 10.1001/jama.2016.16840
2.
GuyattGH.Measuring health-related quality of life. Ann Intern Med, 1993; 118(8):622; doi: 10.7326/0003-4819-118-8-199304150-00009
3.
WeldringT, SmithSMS. Article commentary: Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs). Health Serv Insights, 2013; 6:HSI.S11093; doi: 10.4137/HSI.S11093
4.
HoergerM, GreerJA, JacksonVA, et al.Defining the elements of early palliative care that are associated with patient-reported outcomes and the delivery of end-of-life care. J Clin Oncol, 2018; 36(11):1096–1102; doi: 10.1200/JCO.2017.75.6676
5.
ZimmermannC, RiechelmannR, KrzyzanowskaM, et al.Effectiveness of specialized palliative care: A systematic review. JAMA, 2008; 299(14):1698–1709; doi: 10.1001/jama.299.14.1698
6.
QuinnKL, ShurrabM, GitauK, et al.Association of receipt of palliative care interventions with health care use, quality of life, and symptom burden among adults with chronic noncancer illness: A systematic review and meta-analysis. JAMA, 2020; 324(14):1439–1450; doi: 10.1001/jama.2020.14205
7.
EiserC, JenneyM. Measuring quality of life. Arch Dis Child, 2007; 92(4):348–350; doi: 10.1136/adc.2005.086405
8.
AlbersG, EchteldMA, de VetHCW, et al.Evaluation of quality-of-life measures for use in palliative care: A systematic review. Palliat Med, 2010; 24(1):17–37; doi: 10.1177/0269216309346593
9.
DavisMP, HuiD. Quality of life in palliative care. Expert Rev Qual Life Cancer Care, 2017; 2(6):293–302; doi: 10.1080/23809000.2017.1400911
10.
McmillanSC.Quality-of-life assessment in palliative care. Cancer Control, 1996; 3(3):223–229; doi: 10.1177/107327489600300304
11.
MassaroT, McMillanSC. Instruments for assessing quality of life in palliative care settings. Int J Palliat Nurs, 2000; 6(9):429–433; doi: 10.12968/ijpn.2000.6.9.9054
12.
TerweeCB, PrinsenCAC, ChiarottoA, et al.COSMIN methodology for evaluating the content validity of patient-reported outcome measures: A Delphi study. Qual Life Res, 2018; 27(5):1159–1170; doi: 10.1007/s11136-018-1829-0
13.
KavalieratosD, KamalAH, AbernethyAP, et al.Comparing unmet needs between community-based palliative care patients with heart failure and patients with cancer. J Palliat Med, 2014; 17(4):475–481; doi: 10.1089/jpm.2013.0526
14.
MoherD.Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med, 2009; 151(4):264; doi: 10.7326/0003-4819-151-4-200908180-00135
15.
AhmedA, AronowWS, FlegJL. Higher New York Heart Association classes and increased mortality and hospitalization in patients with heart failure and preserved left ventricular function. Am Heart J, 2006; 151(2):444–450; doi: 10.1016/j.ahj.2005.03.066
16.
SimpsonJ, JhundPS, LundLH, et al.Prognostic models derived in PARADIGM-HF and validated in ATMOSPHERE and the Swedish heart failure registry to predict mortality and morbidity in chronic heart failure. JAMA Cardiol, 2020; 5(4):432–441; doi: 10.1001/jamacardio.2019.5850
BenzaRL, Gomberg-MaitlandM, ElliottCG, et al.Predicting survival in patients with pulmonary arterial hypertension: The REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest, 2019; 156(2):323–337; doi: 10.1016/j.chest.2019.02.004
19.
BoutouAK, ShrikrishnaD, TannerRJ, et al.Lung function indices for predicting mortality in COPD. Eur Respir J, 2013; 42(3):616–625; doi: 10.1183/09031936.00146012
20.
ShavelleRM, PaculdoDR, KushSJ, et al.Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up Study. Int J Chron Obstruct Pulmon Dis, 2009; 4:137–148; doi: 10.2147/copd.s5237
21.
CelliBR, CoteCG, MarinJM, et al.The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med, 2004; 350(10):1005–1012; doi: 10.1056/NEJMoa021322
22.
AevarssonO, SvanborgA, SkoogI. Seven-year survival rate after age 85 years: Relation to Alzheimer disease and vascular dementia. Arch Neurol, 1998; 55(9):1226–1232; doi: 10.1001/archneur.55.9.1226
23.
SampsonEL, LeurentB, BlanchardMR, et al.Survival of people with dementia after unplanned acute hospital admission: A prospective cohort study. Int J Geriatr Psychiatry, 2013; 28(10):1015–1022; doi: 10.1002/gps.3919
24.
PytkaD, Czarkowska-PaczekB. Cognitive function is a prognostic factor for mortality of nursing home residents during a 3-year observational period. Dement Geriatr Cogn Dis Extra, 2020; 10(3):163–171; doi: 10.1159/000509543
25.
BrownMA, SampsonEL, JonesL, et al.Prognostic indicators of 6-month mortality in elderly people with advanced dementia: A systematic review. Palliat Med, 2013; 27(5):389–400; doi: 10.1177/0269216312465649
26.
AlcazS, JarebinskiM, Pekmezović T, et al. [Survival in amyotrophic lateral sclerosis]. Srp Arh Celok Lek, 1997; 125(1–2):19–23.
27.
WolfJ, SaferA, WöhrleJC, et al.Factors predicting one-year mortality in amyotrophic lateral sclerosis patients—Data from a population-based registry. BMC Neurol, 2014; 14:197; doi: 10.1186/s12883-014-0197-9
28.
United States Renal Data System. 2017 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda, MD, USA; 2017.
29.
WachtermanMW, O'HareAM, RahmanO-K, et al.One-year mortality after dialysis initiation among older adults. JAMA Intern Med, 2019; 179(7):987; doi: 10.1001/jamainternmed.2019.0125
30.
SchmidtRJ, LandryDL, CohenL, et al.Derivation and validation of a prognostic model to predict mortality in patients with advanced chronic kidney disease. Nephrol Dial Transplant, 2019; 34(9):1517–1525; doi: 10.1093/ndt/gfy305
31.
HansonLC, ErnecoffNC, WessellKL, et al.Mortality risk for patients with stage IV cancer and acute illness hospitalization. J Pain Symptom Manage, 2021; 61(4):797–804; doi: 10.1016/j.jpainsymman.2020.10.015
32.
BørøS, ThoresenS, Helland Å. Improvements in survival for patients with stage IV adenocarcinoma in the lung, diagnosed between 2010–2020—A population-based registry study from Norway. Front Oncol, 2022; 12:1017902; doi: 10.3389/fonc.2022.1017902
33.
WangJ, LiS, LiuY, et al.Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med, 2020; 9(1):361–373; doi: 10.1002/cam4.2673
34.
EngLG, DawoodS, SopikV, et al.Ten-year survival in women with primary stage IV breast cancer. Breast Cancer Res Treat, 2016; 160(1):145–152; doi: 10.1007/s10549-016-3974-x
35.
MotzerRJ, MazumdarM, BacikJ, et al.Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 1999; 17(8):2530–2540; doi: 10.1200/JCO.1999.17.8.2530
36.
BajorinDF, DoddPM, MazumdarM, et al.Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol, 1999; 17(10):3173–3181; doi: 10.1200/JCO.1999.17.10.3173
37.
PrinsenCAC, MokkinkLB, BouterLM, et al.COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res, 2018; 27(5):1147–1157; doi: 10.1007/s11136-018-1798-3
38.
MokkinkLB, de VetHCW, PrinsenCAC, et al.COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures. Qual Life Res, 2018; 27(5):1171–1179; doi: 10.1007/s11136-017-1765-4
39.
DeVonHA, BlockME, Moyle-WrightP, et al.A psychometric toolbox for testing validity and reliability. J Nurs Scholarsh, 2007; 39(2):155–164; doi: 10.1111/j.1547-5069.2007.00161.x
40.
EbrahimiN, NaghdiS, AnsariNN, et al.Statistical validity and reliability of the Persian version of the Western Ontario Meniscal Evaluation Tool (WOMET) according to the COSMIN checklist. BMC Musculoskelet Disord, 2020; 21(1):183; doi: 10.1186/s12891-020-3171-2
41.
FinkA.Survey research methods. In: International Encyclopedia of Education. 3rd ed. (PetersonP, BakerE, McGawB. eds.) Elsevier; 2010; pp. 152–160; doi: 10.1016/B978-0-08-044894-7.00296-7
42.
LynnMR.Determination and quantification of content validity. Nurs Res, 1986; 35(6):382–385.
43.
ZamanzadehV, GhahramanianA, RassouliM, et al.Design and implementation content validity study: Development of an instrument for measuring patient-centered communication. J Caring Sci, 2015; 4(2):165–178; doi: 10.15171/jcs.2015.017
44.
CellaD, HahnEA, JensenSE, et al. Patient-Reported Outcomes in Performance Measurement. RTI Press: Research Triangle Park, NC, USA; 2015.
45.
BellamyN.2—Principles of clinical outcome assessment. In: Rheumatology, 6th ed. (Hochberg MC, Silman AJ, Smolen JS, et al. eds.) Mosby: Philadelphia, PA, USA; 2015; pp. 9–19; doi: 10.1016/B978-0-323-09138-1.00002-4
46.
PiedmontRL.Criterion validity. In: Encyclopedia of Quality of Life and Well-Being Research. Springer Netherlands: Dordrecht; 2014; pp. 1348–1348; doi: 10.1007/978-94-007-0753-5_618
47.
AdamsH, CervantesP, JangJ, et al.Chapter 25—standardized assessment. In: Practical resources for the mental health professional, evidence-based treatment for children with autism. (GranpeeshehD, TarboxJ, NajdowskiAC, et al. eds.) Academic Press; 2014; pp. 501–516; doi: 10.1016/B978-0-12-411603-0.00025-2
48.
DanceyC, ReidyJ. Statistics Without Maths for Psychology. 3rd ed. Prentice Hall; 2004.
49.
MukakaMM.Statistics corner: A guide to appropriate use of correlation coefficient in medical research. Malawi Med J, 2012; 24(3):69–71.
50.
PolitDF, BeckCT, OwenS v. Is the CVI an acceptable indicator of content validity? Appraisal and recommendations. Res Nurs Health, 2007; 30(4):459–467; doi: 10.1002/nur.20199
51.
GadeG, VenohrI, ConnerD, et al.Impact of an inpatient palliative care team: A randomized controlled trial. J Palliat Med, 2008; 11(2):180–190; doi: 10.1089/jpm.2007.0055
52.
HarrisonMB, BrowneGB, RobertsJ, et al.Quality of life of individuals with heart failure: A randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care, 2002; 40(4):271–282; doi: 10.1097/00005650-200204000-00003
53.
WongFKY, NgAYM, LeePH, et al.Effects of a transitional palliative care model on patients with end-stage heart failure: A randomised controlled trial. Heart, 2016; 102(14):1100; doi: 10.1136/heartjnl-2015-308638
54.
MurraySA.Dying of lung cancer or cardiac failure: Prospective qualitative interview study of patients and their carers in the community. BMJ, 2002; 325(7370):929–929; doi: 10.1136/bmj.325.7370.929
55.
SteinhauserKE, ArnoldRM, OlsenMK, et al.Comparing three life-limiting diseases: Does diagnosis matter or is sick, sick?. J Pain Symptom Manage, 2011; 42(3):331–341; doi: 10.1016/j.jpainsymman.2010.11.006
56.
BreitbartW, GibsonC, PoppitoSR, et al.Psychotherapeutic interventions at the end of life: A focus on meaning and spirituality. Can J Psychiatry, 2004; 49(6):366–372; doi: 10.1177/070674370404900605
ShresthaA, MartinC, BurtonM, et al.Quality of life versus length of life considerations in cancer patients: A systematic literature review. Psychooncology, 2019; 28(7):1367–1380; doi: 10.1002/pon.5054
60.
WooJ, LoR, ChengJOY, et al.Quality of end-of-life care for non-cancer patients in a non-acute hospital. J Clin Nurs, 2011; 20(13–14):1834–1841; doi: 10.1111/j.1365-2702.2010.03673.x
61.
CurtisJR, PatrickDL, EngelbergRA, et al.A measure of the quality of dying and death. Initial validation using after-death interviews with family members. J Pain Symptom Manage, 2002; 24(1):17–31; doi: 10.1016/s0885-3924(02)00419-0
62.
SteinhauserKE, ClippEC, BosworthHB, et al.Measuring quality of life at the end of life: Validation of the QUAL-E. Palliat Support Care, 2004; 2(1):3–14; doi: 10.1017/s1478951504040027
63.
CohenSR, MountBM, StrobelMG, et al.The McGill Quality of Life Questionnaire: A measure of quality of life appropriate for people with advanced disease. A preliminary study of validity and acceptability. Palliat Med, 1995; 9(3):207–219; doi: 10.1177/026921639500900306
64.
ByockIR, MerrimanMP. Measuring quality of life for patients with terminal illness: The Missoula-VITAS quality of life index. Palliat Med, 1998; 12(4):231–244; doi: 10.1191/026921698670234618
65.
AaronsonNK, AhmedzaiS, BergmanB, et al.The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993; 85(5):365–376; doi: 10.1093/jnci/85.5.365
66.
MystakidouK, TsilikaE, KoulouliasV, et al.The “Palliative Care Quality of Life Instrument (PQLI)” in terminal cancer patients. Health Qual Life Outcomes, 2004; 2(1):8; doi: 10.1186/1477-7525-2-8
67.
CellaDF, TulskyDS, GrayG, et al.The Functional Assessment of Cancer Therapy Scale: Development and validation of the general measure. J Clin Oncol, 1993; 11(3):570–579; doi: 10.1200/JCO.1993.11.3.570
68.
BakitasM, LyonsKD, HegelMT, et al.Effects of a palliative care intervention on clinical outcomes in patients with advanced cancer. JAMA, 2009; 302(7):741; doi: 10.1001/jama.2009.1198
69.
Hoomani MajdabadiF, AshktorabT, IlkhaniM. Impact of palliative care on quality of life in advanced cancer: A meta-analysis of randomised controlled trials. Eur J Cancer Care (Engl), 2022; 31(6):e13647; doi: 10.1111/ecc.13647
70.
ShihH-H, ChangH-J, HuangT-W. Effects of early palliative care in advanced cancer patients: A meta-analysis. Am J Hosp Palliat Med, 2022; 39(11):1350–1357; doi: 10.1177/10499091221075570
71.
GautamaMSN, DamayantiA, KhusniaAF. Impact of early palliative care to improve quality of life of advanced cancer patients: A meta-analysis of randomised controlled trials. Indian J Palliat Care, 2022; 0:1; doi: 10.25259/IJPC_153_2022
72.
TemelJS, GreerJA, MuzikanskyA, et al.Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med, 2010; 363(8):733–742; doi: 10.1056/NEJMoa1000678
73.
HoergerM, WayserGR, SchwingG, et al.Impact of interdisciplinary outpatient specialty palliative care on survival and quality of life in adults with advanced cancer: A meta-analysis of randomized controlled trials. Ann Behav Med, 2019; 53(7):674–685; doi: 10.1093/abm/kay077
74.
BakitasMA, TostesonTD, LiZ, et al.Early versus delayed initiation of concurrent palliative oncology care: Patient outcomes in the ENABLE III randomized controlled trial. J Clin Oncol, 2015; 33(13):1438–1445; doi: 10.1200/JCO.2014.58.6362
75.
BorgsteedeSD, DeliensL, FranckeAL, et al.Defining the patient population: One of the problems for palliative care research. Palliat Med, 2006; 20(2):63–68; doi: 10.1191/0269216306pm1112oa
76.
KelleyAS, Bollens-LundE. Identifying the population with serious illness: The “denominator” challenge. J Palliat Med, 2018; 21(S2):S-7–S-16; doi: 10.1089/jpm.2017.0548
77.
McNamaraB, RosenwaxLK, HolmanCDJ. A method for defining and estimating the palliative care population. J Pain Symptom Manage, 2006; 32(1):5–12; doi: 10.1016/j.jpainsymman.2005.12.018
78.
van MechelenW, AertgeertsB, de CeulaerK, et al.Defining the palliative care patient: A systematic review. Palliat Med, 2013; 27(3):197–208; doi: 10.1177/0269216311435268
79.
DownarJ, GoldmanR, PintoR, et al.The “surprise question” for predicting death in seriously ill patients: A systematic review and meta-analysis. Can Med Assoc J, 2017; 189(13):E484–E493; doi: 10.1503/cmaj.160775
80.
BourkeSC, McCollE, ShawPJ, et al.Validation of quality of life instruments in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord, 2004; 5(1):55–60; doi: 10.1080/14660820310016066
81.
CohenSR, MountBM, BrueraE, et al.Validity of the McGill Quality of Life Questionnaire in the Palliative Care Setting: A multi-centre Canadian study demonstrating the importance of the existential domain. Palliat Med, 1997; 11(1):3–20; doi: 10.1177/026921639701100102
82.
KingMT, AgarM, CurrowDC, et al.Assessing quality of life in palliative care settings: Head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7). Support Care Cancer, 2020; 28(1):141–153; doi: 10.1007/s00520-019-04754-9
83.
LoRSK, WooJ, ZhocKCH, et al.Cross-cultural validation of the McGill Quality of Life questionnaire in Hong Kong Chinese. Palliat Med, 2001; 15(5):387–397; doi: 10.1191/026921601680419438
84.
LyonsKD, BakitasM, HegelMT, et al.Reliability and validity of the functional assessment of chronic illness therapy-palliative care (FACIT-Pal) scale. J Pain Symptom Manage, 2009; 37(1):23–32; doi: 10.1016/j.jpainsymman.2007.12.015
85.
PickardAS, De LeonMC, KohlmannT, et al.Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients. Med Care, 2007; 45(3):259–263; doi: 10.1097/01.mlr.0000254515.63841.81
86.
TeckleP, PeacockS, McTaggart-CowanH, et al.The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. Health Qual Life Outcomes, 2011; 9:106; doi: 10.1186/1477-7525-9-106
87.
TerretC, PérolD, AlbrandG, et al.Quality of life in geriatric oncology-an evaluation of standard questionnaires in elderly men with urological malignancies. Crit Rev Oncol Hematol, 2011; 77(3):201–209; doi: 10.1016/j.critrevonc.2010.02.008
88.
WeitznerMA, MeyersCA, GelkeCK, et al.The Functional Assessment of Cancer Therapy (FACT) Scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer, 1995; 75(5):1151–1161; doi: 10.1002/1097-0142(19950301)75:5<1151::aid-cncr2820750515>3.0.co;2-q
89.
ChenX, XinY, HuW, et al.Quality of life and outcomes in heart failure patients with ejection fractions in different ranges. PLoS One, 2019; 14(6):e0218983; doi: 10.1371/journal.pone.0218983
90.
ChuaR, KeoghAM, BythK, et al.Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J, 2006; 36(11):705–710; doi: 10.1111/j.1445-5994.2006.01169.x
91.
Estrada ÁlvarezJM, Ossa GarcíaX, del Quijano del GordoCI, et al.Validation of the chronic respiratory questionnaire in the Colombian population with chronic obstructive pulmonary disease. Qual Life Res, 2015; 24(8):2039–2044; doi: 10.1007/s11136-015-0939-1
92.
GeschkeK, FellgiebelA, LauxN, et al.Quality of life in Dementia: Impact of cognition and insight on applicability of the SF-36. Am J Geriatr Psychiatry, 2013; 21(7):646–654; doi: 10.1016/j.jagp.2012.12.014
93.
GreenCP, PorterCB, BresnahanDR, et al.Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure. J Am Coll Cardiol, 2000; 35(5):1245–1255; doi: 10.1016/s0735-1097(00)00531-3
94.
HeoS, MoserDK, RiegelB, et al.Testing the psychometric properties of the Minnesota Living with Heart Failure questionnaire. Nurs Res, 2005; 54(4):265–272; doi: 10.1097/00006199-200507000-00009
95.
HoeJ, KatonaC, RochB, et al.Use of the QOL-AD for measuring quality of life in people with severe dementia—The LASER-AD study. Age Ageing, 2005; 34(2):130–135; doi: 10.1093/ageing/afi030
96.
HoldenSK, KoljackCE, PrizerLP, et al.Measuring quality of life in palliative care for Parkinson's disease: A clinimetric comparison. Parkinsonism Relat Disord, 2019; 65:172–177; doi: 10.1016/j.parkreldis.2019.06.018
97.
LogsdonRG, GibbonsLE, McCurrySM, et al.Quality of life in Alzheimer's Disease: Patient and caregiver reports. J Ment Health Aging, 1999; 5(1):21–32.
98.
NetoJFR, FerrazMB, CendorogloM, et al.Quality of life at the initiation of maintenance dialysis treatment—a comparison between the SF-36 and the KDQ questionnaires. Qual Life Res, 2000; 9(1):101–107; doi: 10.1023/a:1008918609281
99.
NolanCM, LongworthL, LordJ, et al.The EQ-5D-5L health status questionnaire in COPD: Validity, responsiveness and minimum important difference. Thorax, 2016; 71(6):493–500; doi: 10.1136/thoraxjnl-2015-207782
100.
ThorgrimsenL, SelwoodA, SpectorA, et al.Whose quality of life is it anyway? The validity and reliability of the Quality of Life-Alzheimer's Disease (QoL-AD) scale. Alzheimer Dis Assoc Disord, 2003; 17(4):201–208; doi: 10.1097/00002093-200310000-00002
101.
WijkstraPJ, van AltenaR, OttenV, et al.Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax, 1994; 49(5):465–467; doi: 10.1136/thx.49.5.465
102.
YangF, LauT, LeeE, et al.Comparison of the preference-based EQ-5D-5L and SF-6D in patients with end-stage renal disease (ESRD). Eur J Health Econ, 2015; 16(9):1019–1026; doi: 10.1007/s10198-014-0664-7
103.
HerdmanM, GudexC, LloydA, et al.Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res, 2011; 20(10):1727–1736; doi: 10.1007/s11136-011-9903-x
104.
PetermanAH, FitchettG, BradyMJ, et al.Measuring spiritual well-being in people with cancer: The functional assessment of chronic illness therapy—Spiritual Well-being Scale (FACIT-Sp). Ann Behav Med, 2002; 24(1):49–58.
105.
WareJE, SherbourneCD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care, 1992; 30(6):473–483.
106.
MchorneyCA, JohneW, AnastasiaeR. The MOS 36-item short-form health survey (SF-36). Med Care, 1993; 31(3):247–263; doi: 10.1097/00005650-199303000-00006
107.
GuyattGH, NogradiS, HalcrowS, et al.Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med, 1989; 4(2):101–107; doi: 10.1007/BF02602348
108.
LeeDTF, YuDSF, WooJ. Validation of the Chronic Heart Failure Questionnaire (Chinese version). Qual Life Res, 2005; 14(5):1421–1426; doi: 10.1007/s11136-004-4768-x
109.
GuyattGH, BermanLB, TownsendM, et al.A measure of quality of life for clinical trials in chronic lung disease. Thorax, 1987; 42(10):773–778; doi: 10.1136/thx.42.10.773
110.
SpertusJA, JonesPG. Development and validation of a short version of the kansas city cardiomyopathy questionnaire. Circ Cardiovasc Qual Outcomes, 2015; 8(5):469–476; doi: 10.1161/CIRCOUTCOMES.115.001958
111.
RectorT.Patient's self-assessment of their congestive heart failure: II. Content, reli-ability and validity of a new measure-The Minnesota Living with Heart Failure Questionnaire. Heart Fail, 1987; 3:198.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
